vs

Side-by-side financial comparison of Porch Group, Inc. (PRCH) and TG THERAPEUTICS, INC. (TGTX). Click either name above to swap in a different company.

TG THERAPEUTICS, INC. is the larger business by last-quarter revenue ($192.6M vs $121.1M, roughly 1.6× Porch Group, Inc.). TG THERAPEUTICS, INC. runs the higher net margin — 12.0% vs -3.9%, a 15.8% gap on every dollar of revenue. On growth, Porch Group, Inc. posted the faster year-over-year revenue change (100.0% vs 78.0%). Over the past eight quarters, TG THERAPEUTICS, INC.'s revenue compounded faster (74.2% CAGR vs 26.4%).

Porch is a website that tries to connect homeowners with local home improvement contractors. The site features advice articles, cost guide, and online booking for over 160 home projects.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with B-cell malignancies, autoimmune diseases and neurodegenerative disorders. Its core operating markets are North America and Europe, with key product segments including targeted monoclonal antibodies and oral small molecule treatments.

PRCH vs TGTX — Head-to-Head

Bigger by revenue
TGTX
TGTX
1.6× larger
TGTX
$192.6M
$121.1M
PRCH
Growing faster (revenue YoY)
PRCH
PRCH
+22.0% gap
PRCH
100.0%
78.0%
TGTX
Higher net margin
TGTX
TGTX
15.8% more per $
TGTX
12.0%
-3.9%
PRCH
Faster 2-yr revenue CAGR
TGTX
TGTX
Annualised
TGTX
74.2%
26.4%
PRCH

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
PRCH
PRCH
TGTX
TGTX
Revenue
$121.1M
$192.6M
Net Profit
$-4.7M
$23.0M
Gross Margin
52.7%
80.2%
Operating Margin
34.7%
26.2%
Net Margin
-3.9%
12.0%
Revenue YoY
100.0%
78.0%
Net Profit YoY
2.0%
-1.3%
EPS (diluted)
$-0.04
$0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRCH
PRCH
TGTX
TGTX
Q1 26
$121.1M
Q4 25
$112.3M
$192.6M
Q3 25
$115.1M
$161.7M
Q2 25
$107.0M
$141.1M
Q1 25
$84.5M
$120.9M
Q4 24
$75.3M
$108.2M
Q3 24
$77.7M
$83.9M
Q2 24
$75.9M
$73.5M
Net Profit
PRCH
PRCH
TGTX
TGTX
Q1 26
$-4.7M
Q4 25
$-3.5M
$23.0M
Q3 25
$-10.9M
$390.9M
Q2 25
$2.6M
$28.2M
Q1 25
$8.4M
$5.1M
Q4 24
$30.5M
$23.3M
Q3 24
$14.4M
$3.9M
Q2 24
$-64.3M
$6.9M
Gross Margin
PRCH
PRCH
TGTX
TGTX
Q1 26
52.7%
Q4 25
99.5%
80.2%
Q3 25
75.6%
82.6%
Q2 25
70.9%
86.6%
Q1 25
77.4%
87.1%
Q4 24
85.8%
Q3 24
79.4%
88.9%
Q2 24
22.1%
88.7%
Operating Margin
PRCH
PRCH
TGTX
TGTX
Q1 26
34.7%
Q4 25
14.7%
26.2%
Q3 25
14.2%
18.2%
Q2 25
4.7%
24.7%
Q1 25
-1.5%
7.1%
Q4 24
33.3%
27.7%
Q3 24
-3.2%
14.8%
Q2 24
-69.2%
12.0%
Net Margin
PRCH
PRCH
TGTX
TGTX
Q1 26
-3.9%
Q4 25
-3.1%
12.0%
Q3 25
-9.4%
241.7%
Q2 25
2.4%
20.0%
Q1 25
9.9%
4.2%
Q4 24
40.5%
21.6%
Q3 24
18.5%
4.6%
Q2 24
-84.8%
9.4%
EPS (diluted)
PRCH
PRCH
TGTX
TGTX
Q1 26
$-0.04
Q4 25
$0.00
$0.14
Q3 25
$-0.10
$2.43
Q2 25
$0.00
$0.17
Q1 25
$0.07
$0.03
Q4 24
$0.34
$0.16
Q3 24
$0.12
$0.02
Q2 24
$-0.65
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRCH
PRCH
TGTX
TGTX
Cash + ST InvestmentsLiquidity on hand
$68.4M
$142.0M
Total DebtLower is stronger
$391.3M
Stockholders' EquityBook value
$26.3M
$648.0M
Total Assets
$806.6M
$1.1B
Debt / EquityLower = less leverage
14.87×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRCH
PRCH
TGTX
TGTX
Q1 26
$68.4M
Q4 25
$57.3M
$142.0M
Q3 25
$85.0M
$131.6M
Q2 25
$79.8M
$251.9M
Q1 25
$70.4M
$276.2M
Q4 24
$191.7M
$311.0M
Q3 24
$238.6M
$341.0M
Q2 24
$308.4M
$217.3M
Total Debt
PRCH
PRCH
TGTX
TGTX
Q1 26
$391.3M
Q4 25
$392.8M
Q3 25
$387.1M
Q2 25
$394.1M
Q1 25
$409.2M
Q4 24
$403.9M
Q3 24
$399.0M
Q2 24
$436.8M
Stockholders' Equity
PRCH
PRCH
TGTX
TGTX
Q1 26
$26.3M
Q4 25
$-24.6M
$648.0M
Q3 25
$-27.9M
$607.2M
Q2 25
$-29.3M
$276.4M
Q1 25
$-52.4M
$237.3M
Q4 24
$-43.2M
$222.4M
Q3 24
$-77.0M
$192.2M
Q2 24
$-101.9M
$177.6M
Total Assets
PRCH
PRCH
TGTX
TGTX
Q1 26
$806.6M
Q4 25
$797.4M
$1.1B
Q3 25
$787.7M
$1.0B
Q2 25
$770.7M
$702.6M
Q1 25
$802.3M
$656.7M
Q4 24
$814.0M
$577.7M
Q3 24
$867.3M
$586.0M
Q2 24
$876.1M
$401.2M
Debt / Equity
PRCH
PRCH
TGTX
TGTX
Q1 26
14.87×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRCH
PRCH
TGTX
TGTX
Operating Cash FlowLast quarter
$19.7M
Free Cash FlowOCF − Capex
$19.6M
FCF MarginFCF / Revenue
10.2%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
0.85×
TTM Free Cash FlowTrailing 4 quarters
$-25.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRCH
PRCH
TGTX
TGTX
Q1 26
Q4 25
$1.2M
$19.7M
Q3 25
$40.8M
$-23.2M
Q2 25
$35.6M
$7.4M
Q1 25
$-11.2M
$-28.7M
Q4 24
$-26.6M
$-25.6M
Q3 24
$12.4M
$-12.2M
Q2 24
$-26.0M
$5.5M
Free Cash Flow
PRCH
PRCH
TGTX
TGTX
Q1 26
Q4 25
$1.1M
$19.6M
Q3 25
$40.7M
$-23.2M
Q2 25
$35.4M
$7.4M
Q1 25
$-11.2M
$-28.7M
Q4 24
$-26.8M
$-25.7M
Q3 24
$12.2M
$-12.2M
Q2 24
$-26.0M
FCF Margin
PRCH
PRCH
TGTX
TGTX
Q1 26
Q4 25
1.0%
10.2%
Q3 25
35.4%
-14.4%
Q2 25
33.0%
5.2%
Q1 25
-13.3%
-23.8%
Q4 24
-35.6%
-23.7%
Q3 24
15.7%
-14.6%
Q2 24
-34.3%
Capex Intensity
PRCH
PRCH
TGTX
TGTX
Q1 26
Q4 25
0.1%
0.0%
Q3 25
0.1%
0.0%
Q2 25
0.2%
0.0%
Q1 25
0.1%
0.0%
Q4 24
0.3%
0.0%
Q3 24
0.3%
0.0%
Q2 24
0.1%
0.0%
Cash Conversion
PRCH
PRCH
TGTX
TGTX
Q1 26
Q4 25
0.85×
Q3 25
-0.06×
Q2 25
13.79×
0.26×
Q1 25
-1.33×
-5.67×
Q4 24
-0.87×
-1.10×
Q3 24
0.86×
-3.15×
Q2 24
0.80×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRCH
PRCH

Segment breakdown not available.

TGTX
TGTX

Products$189.1M98%
License$3.5M2%

Related Comparisons